EA201170150A1 - Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона - Google Patents

Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона

Info

Publication number
EA201170150A1
EA201170150A1 EA201170150A EA201170150A EA201170150A1 EA 201170150 A1 EA201170150 A1 EA 201170150A1 EA 201170150 A EA201170150 A EA 201170150A EA 201170150 A EA201170150 A EA 201170150A EA 201170150 A1 EA201170150 A1 EA 201170150A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
nurr
activators
application
group
Prior art date
Application number
EA201170150A
Other languages
English (en)
Other versions
EA018079B1 (ru
Inventor
Бенаисса Бубиа
Бернар Йоханнес Ван Влиет
Якобус Антониус Йозеф Ден Хартог
Эндрю МакКрири
Мирелль Талландье
Мария Йоханна Петронелла Ван Донген
Оливия Пупардин-Оливье
Original Assignee
Лабораториз Фурнье С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораториз Фурнье С.А. filed Critical Лабораториз Фурнье С.А.
Publication of EA201170150A1 publication Critical patent/EA201170150A1/ru
Publication of EA018079B1 publication Critical patent/EA018079B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к производному индола, в особенности терапевтически полезному, выбранному из соединений формулы (I)в которых Rпредставляет собой галоген или трифторметильную группу, Rпредставляет собой атом водорода или С-C-алкильную группу, Rпредставляет собой изопропильную (1-метилэтильную) группу или трет-бутильную (1,1-диметилэтильную) группу и n равно 3 или 4, а также фармацевтически приемлемым солям указанных соединений формулы (I). Настоящее изобретение может быть использовано при лечении нейродегенеративных заболеваний и, более конкретно, болезни Паркинсона.
EA201170150A 2008-07-10 2009-07-09 Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона EA018079B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0854712A FR2933609B1 (fr) 2008-07-10 2008-07-10 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
PCT/FR2009/051372 WO2010004221A2 (fr) 2008-07-10 2009-07-09 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson

Publications (2)

Publication Number Publication Date
EA201170150A1 true EA201170150A1 (ru) 2011-06-30
EA018079B1 EA018079B1 (ru) 2013-05-30

Family

ID=40297845

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170150A EA018079B1 (ru) 2008-07-10 2009-07-09 Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона

Country Status (28)

Country Link
US (1) US8575210B2 (ru)
EP (1) EP2300424B1 (ru)
JP (1) JP5396650B2 (ru)
KR (1) KR101606184B1 (ru)
CN (1) CN102112441B (ru)
AR (1) AR072718A1 (ru)
AT (1) ATE541831T1 (ru)
AU (1) AU2009269842B2 (ru)
BR (1) BRPI0915627A8 (ru)
CA (1) CA2730302C (ru)
CY (1) CY1112638T1 (ru)
DK (1) DK2300424T3 (ru)
EA (1) EA018079B1 (ru)
ES (1) ES2381180T3 (ru)
FR (1) FR2933609B1 (ru)
HK (1) HK1154852A1 (ru)
HR (1) HRP20120231T1 (ru)
IL (1) IL210386A (ru)
MX (1) MX2011000353A (ru)
MY (1) MY155959A (ru)
PL (1) PL2300424T3 (ru)
PT (1) PT2300424E (ru)
SA (1) SA109300453B1 (ru)
SI (1) SI2300424T1 (ru)
TW (1) TWI414289B (ru)
UA (1) UA102397C2 (ru)
WO (1) WO2010004221A2 (ru)
ZA (1) ZA201100041B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2955108B1 (fr) * 2010-01-08 2012-03-16 Fournier Lab Sa Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
KR102059160B1 (ko) 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
US20220016073A1 (en) 2017-11-15 2022-01-20 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
KR101964889B1 (ko) 2017-11-17 2019-04-02 한국생명공학연구원 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
KR20240020098A (ko) 2022-08-05 2024-02-14 엠테라파마 주식회사 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373240B1 (en) * 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
FR2903106B1 (fr) 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL210386A0 (en) 2011-03-31
US20110178150A1 (en) 2011-07-21
JP2011527326A (ja) 2011-10-27
AU2009269842A1 (en) 2010-01-14
MY155959A (en) 2015-12-31
ATE541831T1 (de) 2012-02-15
SA109300453B1 (ar) 2013-05-18
PT2300424E (pt) 2012-04-27
MX2011000353A (es) 2011-02-22
DK2300424T3 (da) 2012-04-16
IL210386A (en) 2015-09-24
PL2300424T3 (pl) 2012-06-29
HK1154852A1 (en) 2012-05-04
UA102397C2 (ru) 2013-07-10
CA2730302A1 (fr) 2010-01-14
BRPI0915627A2 (pt) 2016-07-26
BRPI0915627A8 (pt) 2017-05-16
ES2381180T3 (es) 2012-05-23
CY1112638T1 (el) 2016-02-10
TW201006468A (en) 2010-02-16
EP2300424A2 (fr) 2011-03-30
US8575210B2 (en) 2013-11-05
FR2933609B1 (fr) 2010-08-27
CN102112441A (zh) 2011-06-29
FR2933609A1 (fr) 2010-01-15
SI2300424T1 (sl) 2012-04-30
KR20110110759A (ko) 2011-10-07
TWI414289B (zh) 2013-11-11
EA018079B1 (ru) 2013-05-30
WO2010004221A3 (fr) 2010-05-06
HRP20120231T1 (hr) 2012-04-30
CN102112441B (zh) 2013-07-10
KR101606184B1 (ko) 2016-03-24
CA2730302C (fr) 2017-03-07
EP2300424B1 (fr) 2012-01-18
JP5396650B2 (ja) 2014-01-22
AR072718A1 (es) 2010-09-15
WO2010004221A2 (fr) 2010-01-14
ZA201100041B (en) 2012-03-28
AU2009269842B2 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
EA201170150A1 (ru) Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
ATE517882T1 (de) Chinolinderivate
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
PH12014500947A1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
TW200616953A (en) Indole, indazole or indoline derivatives
EA201000007A1 (ru) Производные индазоламида
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
EA200802329A1 (ru) Производные триазола ii
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201000098A1 (ru) Производные хиназолинамида
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU